Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study

Seium Neberay, Yodit; Stupp, R; Ruhstaller, T; Gervaz, Pascal; Mentha, Gilles; Philippe, M; Allal, Abdelkarim Said; Trembleau, Christelle; Bauer, J; Morant, Rudolf Hans Joséf; Roth, Arnaud

doi:10.1093/annonc/mdi154

Scientific article

Open access

English

Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study

ContributorsSeium Neberay, Yodit; Stupp, R; Ruhstaller, T; Gervaz, Pascal; Mentha, Gilles; Philippe, M; Allal, Abdelkarim Said; Trembleau, Christelle; Bauer, J; Morant, Rudolf Hans Joséf; Roth, Arnaud

Published inAnnals of oncology, vol. 16, no. 5, p. 762-766

Publication date2005

Abstract

A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC).

Keywords

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
Camptothecin/adverse effects/analogs & derivatives/therapeutic use
Colorectal Neoplasms/drug therapy/mortality/pathology
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Fluorouracil/adverse effects/therapeutic use
Humans
Leucovorin/adverse effects/therapeutic use
Liver Neoplasms/drug therapy/secondary
Lung Neoplasms/drug therapy/secondary
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Organoplatinum Compounds/adverse effects/therapeutic use
Palliative Care
Prognosis
Survival Analysis
Treatment Outcome

Affiliation

Research group

Citation (ISO format)

SEIUM NEBERAY, Yodit et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. In: Annals of oncology, 2005, vol. 16, n° 5, p. 762–766. doi: 10.1093/annonc/mdi154

Article (Published version)

Identifiers

PID : unige:37066
DOI : 10.1093/annonc/mdi154
PMID : 15817597

ISSN of the journal0923-7534

615views

283downloads

Creation05/30/2014 12:46:00 PM

First validation05/30/2014 12:46:00 PM

Update time03/14/2023 9:16:49 PM

Status update03/14/2023 9:16:49 PM

Last indexation01/16/2024 10:47:48 AM

Archive ouverte UNIGE

Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study

A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC).

Technical informations